Aging in chronic lung disease: Will anti-aging therapy be the key to the cure?
Weijie Wang,Kai Zhou,Leyuan Wang,Qiuyan Qin,Huijun Liu,Ling Qin,Ming Yang,Lin Yuan,Chi Liu
DOI: https://doi.org/10.1016/j.ejphar.2024.176846
IF: 5.195
2024-08-03
European Journal of Pharmacology
Abstract:Chronic lung disease is the third leading cause of death globally, imposing huge burden of death, disability and healthcare costs. However, traditional pharmacotherapy has relatively limited effects in improving the cure rate and reducing the mortality of chronic lung disease. Thus, new treatments are urgently needed for the prevention and treatment of chronic lung disease. It is particularly noteworthy that, multiple aging-related phenotypes were involved in the occurrence and development of chronic lung disease, such as blocked proliferation, telomere attrition, mitochondrial dysfunction, epigenetic alterations, altered nutrient perception, stem cell exhaustion, chronic inflammation, etc. Consequently, senescent cells induce a series of pathological changes in the lung, such as immune dysfunction, airway remodeling, oxidative stress and regenerative dysfunction, which is a critical issue that needs special attention in chronic lung diseases. Therefore, anti-aging interventions may bring new insights into the treatment of chronic lung diseases. In this review, we elaborate the involvement of aging in chronic lung disease and further discuss the application and prospects of anti-aging therapy.
pharmacology & pharmacy